{
    "title": "109_hr6123",
    "content": "The Act titled \"Helping Fill the Medicare Rx Gap Act of 2006\" includes provisions for including costs incurred by various healthcare entities in providing prescription drugs towards the annual out of pocket threshold under Part D of Medicare. The Act \"Helping Fill the Medicare Rx Gap Act of 2006\" amends Section 1860D-2(b)(4)(C) of the Social Security Act to specify that certain costs incurred for prescription drugs will be treated as incurred if not reimbursed under specific conditions. The Act \"Helping Fill the Medicare Rx Gap Act of 2006\" specifies that costs for prescription drugs will be treated as incurred if not reimbursed under specific conditions, including payments made under various programs such as State Pharmaceutical Assistance Programs, Indian Health Service, federally qualified health centers, and AIDS Drug Assistance Programs. The Act \"Helping Fill the Medicare Rx Gap Act of 2006\" specifies that costs for prescription drugs will be treated as incurred if not reimbursed under specific conditions, including payments made under various programs such as State Pharmaceutical Assistance Programs, Indian Health Service, federally qualified health centers, and AIDS Drug Assistance Programs. Program under part B of title XXVI of the Public Health Service Act includes subsection (d) hospitals and pharmaceutical manufacturer patient assistance programs. The Act \"Helping Fill the Medicare Rx Gap Act of 2006\" specifies that costs for prescription drugs will be treated as incurred if not reimbursed under specific conditions, including payments made under various programs. Effective January 1, 2006, the amendments apply to costs incurred on or after this date. SEC. 3. PROVIDING A SAFE HARBOR FOR PHARMACEUTICAL MANUFACTURER PATIENT ASSISTANCE PROGRAMS. SEC. 3 amends Section 1128B(b)(3) of the Social Security Act by reorganizing subparagraphs and adding new provisions. The amendments to Section 1128B(b)(3) of the Social Security Act include reorganizing subparagraphs, adding new provisions related to remuneration from pharmaceutical manufacturer patient assistance programs, effective from January 1, 2006."
}